Merck & Company, Inc. to Post Q3 2017 Earnings of $1.01 Per Share, SunTrust Banks Forecasts (NYSE:MRK)
Merck & Company, Inc. (NYSE:MRK) – Research analysts at SunTrust Banks cut their Q3 2017 earnings per share (EPS) estimates for shares of Merck & in a research note issued on Sunday. SunTrust Banks analyst J. Boris now forecasts that the company will earn $1.01 per share for the quarter, down from their prior forecast of $1.03. SunTrust Banks also issued estimates for Merck &’s FY2017 earnings at $3.88 EPS.
Merck & (NYSE:MRK) last posted its earnings results on Friday, July 28th. The company reported $1.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.87 by $0.14. Merck & had a net margin of 17.14% and a return on equity of 25.75%. The business had revenue of $9.93 billion for the quarter, compared to analyst estimates of $9.75 billion. During the same period in the prior year, the company posted $0.93 EPS. The company’s revenue for the quarter was up .9% on a year-over-year basis.
WARNING: “Merck & Company, Inc. to Post Q3 2017 Earnings of $1.01 Per Share, SunTrust Banks Forecasts (NYSE:MRK)” was first posted by Daily Political and is owned by of Daily Political. If you are viewing this article on another publication, it was illegally stolen and republished in violation of US and international copyright and trademark laws. The original version of this article can be viewed at https://www.dailypolitical.com/2017/08/09/merck-company-inc-to-post-q3-2017-earnings-of-1-01-per-share-suntrust-banks-forecasts-nysemrk.html.
Several other research analysts have also weighed in on MRK. Cowen and Company restated a “market perform” rating and set a $68.00 target price on shares of Merck & in a research report on Tuesday, April 11th. Jefferies Group LLC restated an “underperform” rating and set a $51.00 target price (down from $52.00) on shares of Merck & in a research report on Saturday, April 22nd. BMO Capital Markets restated an “outperform” rating and set a $70.00 target price on shares of Merck & in a research report on Sunday, April 23rd. Zacks Investment Research upgraded shares of Merck & from a “hold” rating to a “buy” rating and set a $72.00 target price on the stock in a research report on Wednesday, May 10th. Finally, J P Morgan Chase & Co upped their target price on shares of Merck & from $74.00 to $76.00 and gave the stock an “overweight” rating in a research report on Thursday, May 11th. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating and twelve have given a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus target price of $69.80.
Shares of Merck & (NYSE MRK) opened at 62.32 on Tuesday. The stock’s 50 day moving average is $63.66 and its 200 day moving average is $63.77. The stock has a market capitalization of $170.46 billion, a price-to-earnings ratio of 33.74 and a beta of 0.80. Merck & has a 1-year low of $58.29 and a 1-year high of $66.80.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 6th. Investors of record on Friday, September 15th will be paid a dividend of $0.47 per share. This represents a $1.88 annualized dividend and a dividend yield of 3.02%. The ex-dividend date is Thursday, September 14th. Merck &’s payout ratio is 76.11%.
In related news, Director C Robert Kidder sold 5,000 shares of the company’s stock in a transaction that occurred on Friday, May 12th. The shares were sold at an average price of $63.54, for a total transaction of $317,700.00. Following the transaction, the director now owns 14,317 shares of the company’s stock, valued at $909,702.18. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 0.05% of the company’s stock.
Institutional investors have recently made changes to their positions in the stock. Orbimed Advisors LLC increased its position in shares of Merck & by 19.7% in the fourth quarter. Orbimed Advisors LLC now owns 4,615,200 shares of the company’s stock valued at $271,697,000 after buying an additional 758,400 shares during the last quarter. Sciencast Management LP purchased a new position in shares of Merck & during the fourth quarter valued at about $760,000. Kovitz Investment Group Partners LLC increased its position in shares of Merck & by 5.2% in the fourth quarter. Kovitz Investment Group Partners LLC now owns 6,068 shares of the company’s stock valued at $357,000 after buying an additional 300 shares during the last quarter. Ancora Advisors LLC increased its position in shares of Merck & by 22.2% in the fourth quarter. Ancora Advisors LLC now owns 30,407 shares of the company’s stock valued at $1,789,000 after buying an additional 5,525 shares during the last quarter. Finally, Foresters Asset Management Inc. purchased a new position in shares of Merck & during the fourth quarter valued at about $683,000. 73.73% of the stock is currently owned by institutional investors and hedge funds.
About Merck &
Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.
Receive News & Ratings for Merck & Company Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Company Inc. and related companies with MarketBeat.com's FREE daily email newsletter.